Q1 2019 EPS Estimates for Bristol-Myers Squibb Co Cut by Analyst (BMY)

Bristol-Myers Squibb Co (NYSE:BMY) – Analysts at William Blair cut their Q1 2019 EPS estimates for shares of Bristol-Myers Squibb in a research report issued on Wednesday. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $0.91 per share for the quarter, down from their prior forecast of $0.95. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2019 earnings at $0.95 EPS, Q3 2019 earnings at $0.97 EPS and Q4 2019 earnings at $0.98 EPS.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The firm had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 3.9% on a year-over-year basis.

Other analysts also recently issued research reports about the stock. Morgan Stanley upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $51.56 to $78.00 in a research report on Thursday. Piper Jaffray Companies reiterated a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Vetr upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price target for the company in a research report on Thursday, February 1st. Leerink Swann boosted their price objective on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research note on Tuesday, February 6th. Finally, BMO Capital Markets dropped their price objective on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $66.36.

Bristol-Myers Squibb (NYSE BMY) traded up $3.61 during mid-day trading on Thursday, reaching $68.96. 10,406,399 shares of the company traded hands, compared to its average volume of 8,850,000. Bristol-Myers Squibb has a 1 year low of $51.56 and a 1 year high of $69.43. The stock has a market cap of $113,590.00, a P/E ratio of 29.22, a price-to-earnings-growth ratio of 1.98 and a beta of 1.08. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

The business also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.32%. Bristol-Myers Squibb’s dividend payout ratio is 67.80%.

In other news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction dated Friday, December 15th. The shares were bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

Several large investors have recently bought and sold shares of BMY. Renaissance Technologies LLC boosted its position in shares of Bristol-Myers Squibb by 108.5% in the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after buying an additional 7,020,200 shares in the last quarter. BlackRock Inc. boosted its position in shares of Bristol-Myers Squibb by 5.0% in the 4th quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after buying an additional 4,945,515 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Bristol-Myers Squibb by 185.2% in the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after buying an additional 3,960,191 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after buying an additional 3,735,453 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Bristol-Myers Squibb by 2,990.5% in the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after buying an additional 3,516,536 shares in the last quarter. 69.56% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Q1 2019 EPS Estimates for Bristol-Myers Squibb Co Cut by Analyst (BMY)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://ledgergazette.com/2018/02/15/q1-2019-eps-estimates-for-bristol-myers-squibb-co-cut-by-analyst-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply